Tag Archives: consumer protection

9th Circuit chips away at consumer protection again

Hussain v. Campbell Soup Co., No. 24-6041 (9th Cir. Dec. 10, 2025) Nonprecedential despite a dissent. The majority affirms dismissal of claims in a putative class action suit alleging that Kettle Brand “Air Fried” chips are deceptively labeled as solely … Continue reading →

Posted in Uncategorized | Tagged , | Leave a comment

paying a late-disclosed “drip pricing” fee suffices as injury under Cal’s new law

Chowning v. Tyler Tech., Inc., 2025 WL 3496690, No. 4:25-CV-04009-YGR (N.D. Cal. Dec. 5, 2025) One of the first “drip pricing” cases I’ve seen under California’s new law, which the court reads to enable certain claims over and above previous … Continue reading →

Posted in Uncategorized | Tagged , , | Leave a comment

thorough opinion allows CT’s greenwashing claims against Exxon to proceed

State v. Exxon Mobil Corp., 2025 WL 3459468, No. HHDCV206132568S (Conn. Super. Ct. Nov. 26, 2025) The court allows greenwashing claims against Exxon to proceed under the Connecticut Unfair Trade Practices Act (CUTPA). The state alleged a decades-long “systematic campaign … Continue reading →

Posted in Uncategorized | Tagged , , , | Leave a comment

“abortion pill reversal” proponents engaged in noncommercial speech, 2d Circuit agrees for PI purposes

National Institute of Family and Life Advocates v. James, — F.4th —-, 2025 WL 3439256, No. 24-2481-cv (2d Cir. Dec. 1, 2025) Unlike the similar California proceeding, the district court in NY granted a preliminary injunction against enforcement of consumer … Continue reading →

Posted in Uncategorized | Tagged , , , | Leave a comment

“ambiguity” in consumer protection cases is something different from “ambiguity” in Lanham Act cases: the case of “Naturally Derived”

Kent v. Conopco, Inc., 2025 WL 3296002, No. 25-cv-03660-JCS (N.D. Cal. Nov. 26, 2025) The court allows a claim against “Naturally Derived” personal care products to proceed. “There is no asterisk on the front label linking the claim to a … Continue reading →

Posted in Uncategorized | Tagged , | Leave a comment

“unfair competition” CGL insurance exclusion applies only to competitor claims, not consumer claims

Athena Cosmetics, Inc. v. Great American E&S Ins. Co.,  2025 WL 3304392, No. 2:24-cv-08010-AH-AGRx (C.D. Cal. Nov. 24, 2025) Three underlying putative class actions targeted Athena’s sale of “lash enhancement serums from Athena that contained compounds found in prescription drugs … Continue reading →

Posted in Uncategorized | Tagged , , | Leave a comment

court of appeals refuses to create right of publicity for houses, over dissent

Dihno v. Netflix, Inc., 2025 WL 3280834, B335652 (Cal. Ct. App. Nov. 25, 2025) Over a partial dissent, the court of appeals affirms the rejection of various claims, including CLRA and FAL claims, against Netflix based on its use of … Continue reading →

Posted in Uncategorized | Tagged , , | Leave a comment

Star Wars mod wars: claims over a touted but unreleased mod have to go to trial

Mickelonis v. Aspyr Media, No. 8:23-cv-01220-MWC-ADS, 2025 WL 3050071 (C.D. Cal. Oct. 2, 2025) Interesting video game related dispute: Aspyr develops video games, including by recreating and re-releasing historic games on modern platforms like Steam and Nintendo Switch. Aspyr has … Continue reading →

Posted in Uncategorized | Tagged , | Leave a comment

Reading list: consumer protection and the industries who regularly sue their regulators

Nicholas R. Parrillo, Administrative Law as a Choice of Business Strategy: Comparing the Industries Who Have Routinely Sued Their Regulators with the Industries Who Rarely Have George Washington Law Review, Vol. 93, No. 5, pp. 1031-1195 (2025)  Abstract: For some … Continue reading →

Posted in Uncategorized | Tagged , , | Leave a comment

allegedly false claims for compounded weight loss drugs didn’t plausibly threaten Eli Lilly’s reputation

Eli Lilly & Co. v. Mochi Health Corp., 2025 WL 2998166, No. 25-cv-03534-JSC (N.D. Cal. Oct. 24, 2025) Another of the cases in which Eli Lilly’s attempts to protect its GLP-antagonist market do surprisingly badly, once again highlighting the higher … Continue reading →

Posted in Uncategorized | Tagged , , | Leave a comment